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3. Lamy A, Devereaux PJ, Prabhakaran D,
Taggart DP, Hu S, Paolasso E, et al. Off-pump or
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days. N Engl J Med. 2012;366:1489-97.
http://dx.doi.org/10.1016/
j.jtcvs.2012.08.017Reply to the Editor:
We thank Chahine and colleagues
for their letter in response to our arti-
cle discussing on-pump and off-
pump coronary artery bypass grafting
in patients with left main stem dis-
ease.1 We never claimed that off-
pump coronary artery bypass surgery
is the best strategy for patients with
left main disease. Our conclusion
was that ‘‘off-pump coronary artery
surgery in patients with left main
stem disease is a safe procedure that
will reduce morbidity and mortality
and similar long-term survival com-
pared with conventional on-pump
revascularization.’’
We are aware of the results of the 2
recent randomized studies referred to
in the letter. The Coronary Artery By-
pass Grafting Off or On Pump Revas-
cularization trial2 did not demonstrate
any substantial difference between the
2 techniques, and the study concluded
that ‘‘There was no significant differ-
ence between off-pump and on-pump
CABG with respect to the 30-day
rate of death, myocardial infarction,
stroke, or renal failure requiring dialy-
sis.’’ Those authors go on to say, ‘‘The
use of off-pump CABG resulted in
reduced rates of transfusion, reopera-
tion for perioperative bleeding, res-
piratory complications, and acute
kidney injury but also resulted in an
increased risk of early revasculariza-
tion.’’2 However, investigators in the
Veterans Affairs Randomized On/Off
Bypass trial3 concluded that the
results of surgeries performed off-
pump were inferior to conventional
on-pump coronary artery bypass graft
surgery. That study, as pointed out in1274 The Journal of Thoracic anda recent editorial,4 had several major
limitations. More than 70% of eligi-
ble patients (ie, scheduled for urgent
or elective coronary artery bypass
grafting) were excluded because of
clinical reservations of the surgical
team or small target vessels. This sug-
gests inexperience on the part of sur-
geons in the trial, who were required
to have performed just 20 off-pump
coronary artery bypass procedures
(OPCAB) to participate. Conversion
to on-pump coronary artery bypass,
which is known to increase morbidity
and mortality, occurred in>12% of
cases, much greater than the 1% to
3% reported by centers specializing
in OPCAB. In the OPCAB group,
>50% of patients received red blood
cell transfusions, which contrasts
with the 30% in previous randomized
trials. Finally, only a small minority of
the studied population were high-risk
patients, a group more likely to benefit
from OPCAB.
At the Bristol Heart Institute we
have been performing OPCAB sur-
gery for>17 years. We are a high vol-
ume center, with OPCAB accounting
for 70% of all coronary procedures.
We recognize that OPCAB surgery is
a technically demanding procedure
that should be performed in a high
volume center to obtain optimal out-
come. We think that OPCAB is a tech-
nique for the many and not the few
(both surgeons and patients) but only
with structured training and supervi-
sion in the right environment.4
Finally, with regard to the specific
question on the incidence of stroke, in
our article we reported a similar 0.4%
incidence of transient cerebrovascular
accident (CVA) in both groups and
0% and 0.9% of permanent CVA in
the off-pump and on-pump groups, re-
spectively. With off-pump procedures
it is possible to minimize manipulation
of the aorta because there is no require-
ment for cannulation when performing
total arterial revascularization. How-
ever, in our series a majority of patients
also receivedvein grafts thatwere anas-
tomosed to the ascending aorta usingCardiovascular Surgery c November 20a side bite exclusion clamp. The inci-
dence of CVA was low regardless if
patients were operated on using the
on-pump or off-pump technique. We
have no reason to believe that this infor-
mation is inaccurate given that it was
obtained fromour institution’s prospec-
tively collected database. Permanent
CVA is a clearly defined event that is
most unlikely to have been missed by
our clinicians.
Gianni D. Angelini, MD
Michele Murzi, MD
Bristol Heart Institute
University of Bristol
Bristol, United Kingdom
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PLATELET REACTIVITY IN
CORONARYARTERY BYPASS
GRAFTING PATIENTS
SUGGESTS THE NEED FOR
PERIOPERATIVE PLATELET
FUNCTION TESTING
To the Editor:
With great interestwe have read a re-
cent article from Deja and colleagues1
on preoperative aspirin in an elective
coronary artery bypass grafting popu-
lation. The authors conducted a sin-
gle-center, double-blind, randomized
trial comparing its effects to placebo.
The primary endpoints were more
than 750 mL of bleeding during the
first 12 hours postoperatively and12
Letters to the Editormore than 1000 mL of total discharge
from the chest drains. The secondary
endpoint was a composite of cardio-
vascular death, myocardial infarction,
and repeat revascularization. All pa-
tients discontinued aspirin 7 days
before surgery. The night before sur-
gery, they received either 300 mg of
aspirin or placebo. Starting 6 hours
postoperatively, a daily 300 mg dose
of aspirin was continued in all patients.
The study results in the aspirin group
revealed a significant increase in post-
operative bleeding and a long-term
hazard decrease of nonfatal coronary
events (myocardial infarction and
repeat revascularization). We wish to
point out a few confounders and cur-
rent antiplatelet therapy issues that
we believe readers should consider
when interpreting the study results.
As acknowledgedby the authors, the
contemporary cardiac surgery practice
encourages aspirin administration up
until surgery.Wenoted that one quarter
of the patients had undergone percuta-
neous coronary intervention 4 months
(range, 2-10) before surgery. The rec-
ommendation guidelines for antiplate-
let therapy after percutaneous coronary
intervention suggest that most of those
patients were receiving dual antiplate-
let therapy after undergoing that proce-
dure.2 The authors do not mention if
the patients were taking thienopyri-
dines before surgery. If they were tak-
ing theinopyridines, how many days
before surgery were they told to stop
taking them?We consider this of great
importance for the study end points be-
cause theinopyridines have a much
greater influence on postoperative
bleeding than aspirin.
A major confounder in the present
study we consider to be the lack of
platelet response to aspirin quantifica-
tion. Recent evidence has shown sig-
nificant individual variability in the
response to aspirin and its link to
outcomes.3 The terms ‘‘aspirin resis-
tance’’ and ‘‘high on-treatment resid-
ual platelet reactivity’’ have been
introduced. Accordingly, the reported
prevalence of ‘‘aspirin resistance’’The Journalvaries widely from less than 1% to
61%.4 Platelet function tests, such as
whole blood platelet aggregometry
and impedance aggregometry, quantify
the aspirin response. Just recently, we
published a study addressing the prev-
alence of ‘‘aspirin resistance’’ using
a point-of-care platelet function ana-
lyzer in a coronary artery bypass graft-
ing population.5 According to the
platelet function results, individually
tailored dose-dependent aspirin ther-
apy could be recommended to reduce
adverse effects (eg, bleeding) and pre-
serve the beneficial effects. Continuous
aspirin therapy up until surgery could
prevent preoperative ischemic events,
particularly in the residual platelet
reactivity population. Preoperative dis-
continuation could be advised for those
with a pronounced response to aspirin.
Although it is most likely true that
patients taking preoperative aspirin
bleed more than the patients who
discontinued aspirin and that the inci-
dence of the long-term composite of
cardiovascular death, myocardial in-
farction, and repeat revascularization
could be reduced, it is important to
keep in perspective the limitations of
this study. Additional research and
implementation of platelet function
tests in everyday clinical practice will
only improve patient management
and, hopefully, reduce morbidity and
mortality.
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j.jtcvs.2012.06.059Reply to the Editor:
We would like to thank Kopjar and
colleagues1 for their interest in our
study and comments on our report.
Our study definitely shows that preop-
erative aspirin use increases postoper-
ative bleeding but simultaneously
provides some data to support the be-
lief that it might be acceptable because
of the improved long-term outcome.2
As rightly raised by Kopjar and col-
leagues,1 aspirin resistance constitutes
a major issue in modern cardiology
and cardiac surgery. Its effect on clin-
ical outcome has been established in
many studies.3 The number of aspirin
nonresponders and weak responders
after coronary artery bypass surgery
is estimated to be quite high.4 That
we did not assess platelet function
could, therefore, be considered amajor
limitation of the study. However, the
beauty of a randomized design is
that, by definition, it equalizes the
confounders in both treatment arms.
It is even more so when a study is dou-
ble blinded and placebo controlled, as
ours was. Thus, we believe the results
of our study are sound and valid, even
if the ‘‘aspirin resistance’’ was not
assessed.
In addition, the increased bleeding
incidence in patients receiving aspirin
preoperatively in our study hasy c Volume 144, Number 5 1275
